SRPT News

Key Factors

Recent Updates

Catalyst

Small, Medium, and Large order-size fund flows show positive net inflow trends.

Risk

Technical indicators show 5 bearish signals versus only 1 bullish signal over the period.
Analysts rate the stock with a split of 3 Buy and 2 Strong Sell, indicating strong disagreement.

Generated at22:1003/24/2026by

Aime

Newswire

13:02

Sarepta's 15min chart shows RSI overbought, KDJ death cross.

11:39

Sarepta Therapeutics' Experimental siRNA Therapies Show Promising Early Results, Shares Surge 26%

10:10

Market Rally Fueled by Iran Peace Plan and Cheaper Oil

09:52

Sarepta Therapeutics sees 25% surge in shares after posting positive trial data for muscular dystrophy therapies.

11:55

Sarepta Plans FDA Filings for Full Approval of DMD Therapies

About SRPT

Charts

SectorPharmaceutical

Established Date22/07/1980

Listing Date04/06/1997

ExchangeNASDAQ Stock Exchange

Full-time Employees835

Fiscal Year Ends31/12

Websitewww.sarepta.com

Security TypeCommon stock

Office address215 First Street, Suite 415, Cambridge, MA 02142

Business

Introduction

Sarepta Therapeutics, Inc., was incorporated in Oregon on July 22, 1980. The Company is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapies, gene therapies and other genetic therapies for the treatment of rare diseases. It has developed a variety of approved Duchenne muscular dystrophy treatments and is advancing drug candidates for other neuromuscular and skeletal diseases.